Investor Relations

Press Releases


NanoString Technologies Highlights Advances in Precision Oncology at the 60th Annual Meeting of the American Society of Hematology
40+ Abstracts Highlight the Value of the nCounter Platform in Hematology & Immuno-oncology, Including Thirteen that Demonstrate the Potential Utility of the LymphMark Lymphoma Subtyping Test

SEATTLE, Nov. 29, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the highlights of more than 40 nCounter®-based research abstracts that will be presented at the 60th Annual Meeting of the American Society of Hematology being held December 1-4, in San Diego.

"We’re excited to see the extensive body of nCounter-based clinical and research studies that will be presented by our customers and collaborators at the ASH conference," said Brad Gray, president and chief executive officer of NanoString. "These studies illustrate how the nCounter platform may be used to subtype lymphomas and optimize treatment regimens to contribute to better clinical outcomes for patients."

The ASH Annual Meeting will include at least 14 oral presentations and more than 25 posters in various leukemia, lymphoma, and myeloma malignancies that demonstrate the utility of the nCounter platform across the heme-oncology spectrum.  These include 14 abstracts highlighting the potential clinical utility of NanoString’s nCounter Dx LymphMark™ Lymphoma Subtyping Test (LST) for directing treatment decisions, as well as multiple abstracts highlighting the relevance of the PanCancer IO360™ panel in leukemia and multiple new gene signatures on the nCounter platform. Several important abstracts are summarized below:

  • High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials (Poster #2962)
    • A retrospective analysis of two studies showing that LymphMark identifies ABC-type DLBCL tumors that respond to R2CHOP
       
  • Integration of NanoString Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies (Oral & Poster #676)
    • Profiling DLBCL with both LST and the PanCancer Immune Profiling (PCI) panel provide significant complementary information about prognosis for DLBCL patients
       
  • The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL (Oral & Poster #921)
    • New gene signature from the British Columbia Cancer Agency that may be important in identifying a new subgroup of DLBCL for novel therapeutics such as EZH2 inhibitors
       
  • Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Oral & Poster #444)
    • Results from a collaboration between NanoString, Macrogenics, and Dr. Sergio Rutella from Nottingham Trent University showing that the IO360 panel may be able to identify patients with AML who respond to novel therapeutics
       
  • Elevated LAG-3 Expression in the Tumor Microenvironment of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis (Poster #1576)
    • Profiling of DLBCL samples with LymphMark and PanCancer Immune panel shows significance of LAG3 expression in the ABC and unclassified subgroups may be important in directing immunotherapy combos with PD-1 and LAG3.
       
  • Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (Oral & Poster #764)
    • Results from a collaboration between NanoString, Macrogenics, and Dr. Sergio Rutella from Nottingham Trent University showing that the IO360 panel may be able to identify patients with AML who respond to novel therapeutics

The table below includes a selection of 2018 ASH abstracts that best illustrate the potential clinical utility of nCounter across multiple tumor types. To learn more about the capabilities of the nCounter platform, please visit NanoString at booth #2041 at ASH.

Abstract # Title Hyperlink
1576 Elevated LAG-3 Expression in the Tumor Microenvironment of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis https://ash.confex.com/ash/2018/webprogram/Paper112830.html
676 Integration of NanoString Profiling and Functional Characterization of Oxidative and Replicative Stress Biomarkers Identifies Poor Prognosis MYC/BCL-2 Positive Diffuse Large B-Cell Lymphoma Subsets, Providing Opportunities for Precision Therapies https://ash.confex.com/ash/2018/webprogram/Paper118329.html
764 Phase 1 Cohort Expansion of Flotetuzumab, a CD123×CD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) https://ash.confex.com/ash/2018/webprogram/Paper117085.html
444 Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia https://ash.confex.com/ash/2018/webprogram/Paper111539.html
1627 Argx-110 for Treatment of CD70-Positive Advanced Cutaneous T-Cell Lymphoma in a Phase 1/2 Clinical Trial https://ash.confex.com/ash/2018/webprogram/Paper118204.html
1560 Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 As a Therapeutic Target for Restoring MHC Expression in Diffuse Large B-Cell Lymphoma https://ash.confex.com/ash/2018/webprogram/Paper112010.html
921 The Double-Hit Gene Expression Signature Defines a Clinically and Biologically Distinct Subgroup within GCB-DLBCL https://ash.confex.com/ash/2018/webprogram/Paper116827.html
1567 Large B-Cell Lymphomas in Pediatric and Young Adults Display Clinically Relevant Molecular Features Distinguishable from Adult Counterparts https://ash.confex.com/ash/2018/webprogram/Paper114493.html
2896 Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study https://ash.confex.com/ash/2018/webprogram/Paper117244.html
346 New Genomic Model Integrating Clinical Factors and Gene Mutations to Predict Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP https://ash.confex.com/ash/2018/webprogram/Paper117636.html
2962 High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Prophyling: A Combined Analysis from Two Phase 2 Trials https://ash.confex.com/ash/2018/webprogram/Paper119495.html
1688 Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years https://ash.confex.com/ash/2018/webprogram/Paper116060.html
782 Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study https://ash.confex.com/ash/2018/webprogram/Paper118519.html
2959 Primary Mediastinal B-Cell Lymphoma: Evaluation of Clinicopathologic Diagnosis Compared to Gene Expression Based Diagnosis in a Clinical Trial with CD30+ B-Cell Lymphomas https://ash.confex.com/ash/2018/webprogram/Paper115024.html
3091 Phase 1b/2 Combination Study of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) https://ash.confex.com/ash/2018/webprogram/Paper119990.html
1561 Prediction and Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Cell of Origin (COO) Subtypes Using Genomic Features from Targeted Next-Generation Sequencing https://ash.confex.com/ash/2018/webprogram/Paper116677.html
929 Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach https://ash.confex.com/ash/2018/webprogram/Paper113034.html
1683 Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study https://ash.confex.com/ash/2018/webprogram/Paper118551.html
669 Recurrent IL4R Somatic Mutations in Diffuse Large B-Cell Lymphoma Lead to an Altered Gene Expression Profile and Changes in Tumor Microenvironment Composition https://ash.confex.com/ash/2018/webprogram/Paper110473.html
1845 Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events https://ash.confex.com/ash/2018/webprogram/Paper116293.html
2927 Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis https://ash.confex.com/ash/2018/webprogram/Paper113133.html
2397 The Role of microRNAs in the Pathogenesis of Erdheim-Chester Disease and Their Potential Use As Biomarkers for Diagnosis and Prognosis of the Disease https://ash.confex.com/ash/2018/webprogram/Paper112388.html
1593 Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma https://ash.confex.com/ash/2018/webprogram/Paper112752.html
2847 Enhanced Expression of FGF Signaling in Primary Central Nervous System Lymphoma https://ash.confex.com/ash/2018/webprogram/Paper116416.html
3434 Exploring LAG-3 Expression in Multiple Myeloma Patients Following Autologous Stem Cell Transplant https://ash.confex.com/ash/2018/webprogram/Paper119577.html
4123 The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma https://ash.confex.com/ash/2018/webprogram/Paper115836.html
1570 Enhanced DNA Repair and Genomic Stability in HIV(+) Diffuse Large B Cell Lymphoma of Germinal Center Origin https://ash.confex.com/ash/2018/webprogram/Paper116571.html
1850 mRNA Profiling of CLL Cells Derived from the Blood, Bone Marrow and Lymph Node https://ash.confex.com/ash/2018/webprogram/Paper118264.html
70 Early Prediction of Moderate-Severe Chronic GvHD By Immunity Related Transcriptome https://ash.confex.com/ash/2018/webprogram/Paper119926.html
2977 Clinical Features and Cell of Origin Subtyping Using Gene Expression Profiling in HIV-Negative Patients with Primary Central Nervous System Lymphoma https://ash.confex.com/ash/2018/webprogram/Paper110660.html
1324 Genetic Modulation of Adenosine-to-Inosine RNA Editing Selectively Disrupts Inflammasome and Extracellular Matrix Genes in Multiple Myeloma https://ash.confex.com/ash/2018/webprogram/Paper120326.html
1077 High-Throughput Mirna Analysis Suggests Pro-Inflammatory Profile in Sickle Cell Disease https://ash.confex.com/ash/2018/webprogram/Paper110812.html
355 ICOSL+ Plasmacytoid Dendritic Cells As Biomarker and Inducer of Graft-Versus-Host Disease https://ash.confex.com/ash/2018/webprogram/Paper116417.html
343 A New Stromal Signature Applicable to Formalin-Fixed Paraffin-Embedded Tissues Identifies Patients at Risk in Prospective Clinical Trials of the German High-Grade Non-Hodgkin Lymphoma Study Group https://ash.confex.com/ash/2018/webprogram/Paper112450.html
1621 A Critical Role for Intratumoral and Circulating LAG3 in Classical Hodgkin Lymphoma: Analysis from the Rathl Prospective Phase III International Clinical Trial https://ash.confex.com/ash/2018/webprogram/Paper112008.html

About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 2,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, IO 360, LymphMark, nCounter, and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Contact:

Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768

nano.jpg

Source: NanoString Technologies, Inc.